Tachykinin receptor antagonists in clinical trials.

  title={Tachykinin receptor antagonists in clinical trials.},
  author={Laura Quartara and Maria Altamura and Stefano Evangelista and Carlo A. Maggi},
  journal={Expert opinion on investigational drugs},
  volume={18 12},
Tachykinins (TKs) are small peptides widely distributed in the central and peripheral nervous systems where they act as neurotransmitters. Potent and selective TKs antagonists have been developed in the last 20 years and many efforts have been made to prove their efficacy in the treatment of various diseases. Herein the most prominent results in the clinical development are reported and discussed. For aprepitant, the only compound of this class to have been launched to date, results of clinical… CONTINUE READING